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High-dose chemotherapy with autologous stem cell rescue has been regarded as the standard of care 
for young newly diagnosed myeloma patients. Moreover, the development of new agents with 
potent anti-tumor activity has further improved survival. However, relapse is a continuous risk 
primarily due to the inability of current therapies to eradicate all myeloma cells. Allografting is the 
only potentially curative treatment at least for a subset of multiple myeloma patients due to its well 
documented graft-versus-myeloma effects. Given the high transplant mortality of the high-dose 
myeloablative conditionings used until recently, allografting has for a long time been limited to 
younger relapsed/refractory patients. These limitations have been reduced significantly by the use 
of reduced-intensity conditionings. Although results of recent trials are encouraging, the subset of 
patients who may benefit most from an allograft remains to be determined. An overview of the 
clinical outcomes obtained with allografting and possible future developments are reported. 
Multiple myeloma remains a fatal plasma cell disorder, although progress in the understanding of 
its pathogenesis has identified mechanisms that have recently become targets of new agents with 
potent anti-myeloma activity such as thalidomide and its derivatives, and bortezomib.
1, 2, 3, 4 and 5
 
However, high-dose chemotherapy and autologous stem cell rescue with/without these newer agents 
is still regarded as standard treatment for newly diagnosed myeloma patients younger than 65 
years.
6, 7, 8, 9 and 10
 Patients are almost universally at continuous risk of relapse and only a minority 
live disease-free for longer than 10-15 years.
8 and 9
 In at least a subset of patients, allografting from a 
human leukocyte antigen (HLA)-identical sibling or an unrelated donor appears to be the only 
potentially curative strategy due to the well-documented graft-versus-myeloma effects.
11
 Given the 
high transplant-related mortality and toxicity related to the intense myeloablative conditioning 
regimens employed until recently, allografting has frequently been limited to younger patients at 
relapse or who are refractory to chemotherapy.
12, 13 and 14
 Since the early 2000s, these limitations 
have been dramatically reduced through the introduction of so-called reduced-intensity or 
nonmyeloablative conditioning regimens.
15
 These regimens allowed an increase in the eligible age 
for allografting up to 65-70 years, even in patients with nonhematological comorbidities, and have 
shifted the burden of tumor eradication from chemotherapy to donor T cells.
16 and 17
 In this article we 
will review the current evidence of graft-versus-myeloma effects, and the results obtained with 
conventional myeloablative regimens, and also summarize the results of recent trials with reduced-
intensity conditioning regimens. 
 
Allografting and Graft-Versus-Myeloma Effects 
 
The potentially eradicating effect of an allograft relies on the immune attack of donor-derived T 
cells against myeloma-specific antigens capable of inducing graft-versus-myeloma effects. Direct 
evidence for the existence of such effects was the transfer of myeloma idiotype-specific immunity 
from an immunized marrow donor to the patient.
18
 Other indirect evidence was initially documented 
by the achievement of complete remissions following the infusion of donor-derived lymphocytes or 
discontinuation of immunosuppression in patients who relapsed after an allograft.
19, 20, 21 and 22
 
However, large studies clearly showed that, although donor lymphocyte infusions could induce high 
response rates, durable remissions were achieved only in a few patients. Major toxicity of this cell 
therapy was acute, and chronic graft-versus-host disease (GvHD) was reported in up to 55% and 
26% of patients respectively.
22
 However, some studies reported that the strongest predictors for 
response to donor lymphocyte infusions were acute and chronic GvHD,
23, 24 and 25
 suggesting that 
GvHD and the graft-versus-myeloma mechanism/effect may share the same antigenic targets. 
Overall, chronic GvHD has been associated with longer response duration and overall survival in 
several hematological malignancies treated with an allograft. However, in a recent study by the 
Gruppo Italiano Trapianti di Midollo (GITMO), the development of chronic GvHD did not correlate 
with the achievement of remission and duration of response.
26
 Thus, a graft-versus-myeloma effect 
may also be distinct from chronic GvHD and associated with subclinical graft-versus-host reactions, 
especially after a truly nonmyeloablative conditioning regimen. Moreover, further evidence for 
graft-versus-myeloma effects are the molecular remissions, prelude to possible cure, that are more 
commonly observed after myeloablative allografting as compared to autografting and that can occur 
in up to 50% of patients.
27
 
 
Allografting: Past and Present 
 
Myeloablative Conditionings 
 
The most frequently used myeloablative conditionings have included cyclophosphamide with total 
body irradiation or busulfan, or melphalan and total body irradiation.
12, 13, 14, 28 and 29
 The 
unacceptably high treatment-related mortality of up to 60% has commonly restricted this approach 
to young, usually in their fifth decade, medically fit patients.
12, 13 and 14
 Causes of death were 
primarily regimen-related events, and GvHD and its treatment-related complications, such as 
opportunistic infections. The reason for the high transplant-related mortality reported in myeloma 
compared to other malignancies remains unknown. Theories put forward include detrimental 
myeloma effects on baseline organ functions and/or a severe immunodeficiency that increases the 
risks of toxicities and infections. 
The largest single-center experience on myeloablative allografting comes from the Seattle 
group.
13 and 28
 One hundred thirty-six heavily pretreated or disease-refractory patients younger than 
60 years of age received an allograft between 1987 and 1999 from either a related (84%) or an 
unrelated donor (16%). The authors reported a day-100 transplant-related mortality of 48%. 
Overall, the 5-year survival was 22% with disease-free survival of 14%. Importantly, in 34% of 
patients who achieved post-transplant complete remission, overall and disease-free survivals at 5 
years were 48% and 37%, respectively. Moreover, a subgroup analysis showed that early transplant-
related mortality was approximately 20% for patients with chemo-sensitive disease who were 
transplanted within 1 year from diagnosis. 
Barlogie et al reported on the multicenter prospective randomized US Intergroup Trial S9321.
30
 The 
three-arm study included a myeloablative allograft for newly diagnosed patients younger than 55 
years with an HLA-identical sibling donor. However, this arm was soon closed due to a 53% 
transplant-related mortality rate. Importantly, at the time of publication, 22% of the patients 
enrolled were reported alive and progression-free at 7 years. Moreover, both overall and event-free 
survival curves showed a plateau with follow-up extending to 10 years, likely consistent with a 
cured subgroup of patients. 
The largest retrospective multi-center analysis by the European Bone Marrow Transplant (EBMT) 
registry showed a remarkable improvement in survival in the late 1990s due to a reduction in 
transplant-related mortality through improved supportive care and more careful patient selection.
31
 
In this study, 690 patients, with a median age at transplant of 44 years, who underwent a 
myeloablative allograft were divided into two cohorts: patients who received a bone marrow 
allograft between 1983-1993 and those grafted between 1994-1998. In the latter cohort, some 
patients also received granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood 
hematopoietic cells (PBHCs). Transplant-related mortality at 6 and 24 months was lower in the 
cohort transplanted between 1994-1998 than in the cohort transplanted between 1983-1993 (21% v 
38% and 30% v 46%, respectively). The reduced toxicity led to increases in overall and 
progression-free survivals at 3 years from 35% to 55% and from 7 to 19 months for patients 
transplanted between 1994-1998. Moreover, no differences in clinical outcomes were observed 
between patients who received marrow and those who received PBHCs. 
Comparing results from different studies does not help to establish the real role of myeloablative 
allografting. In fact, most trials are retrospective and their inclusion criteria and pretransplant 
characteristics vary greatly. Despite these selection biases, it is widely assumed that better clinical 
outcomes are associated with patients with chemosensitive myeloma at transplant. In most studies, 
about 50% of these patients achieved complete remission at a median of 3 months from transplant. 
However, late relapses may occur, and in most series, only 10%-25% of patients eventually become 
long-term disease-free survivors and are possibly cured. 
 
Reduced-Intensity Conditionings 
 
Despite the high transplant-related mortality, the association of myeloablative allografting with 
long-term disease-free survival in some patients indicated that graft-versus-myeloma effects may 
have been curative for multiple myeloma. These findings prompted clinicians in the late 1990s to 
explore highly immunosuppressive, though less myelosuppressive and less intense, conditionings 
that could establish stable donor engraftment while reducing transplant-related organ toxicity. These 
more recent conditionings were defined as reduced-intensity or truly nonmyeloablative. The most 
widely used conditioning was originally developed at the Fred Hutchinson Cancer Research Center 
in Seattle and was based on preclinical animal studies that showed that donor cell engraftment could 
be steadily achieved after a truly nonmyeloablative regimen consisting of low-dose total body 
irradiation (200 cGy) followed by intense post-transplant immunosuppression with cyclosporine 
and mycophenolate mofetil.
32
 This strategy was soon translated from the bench to the bedside.
33
 
After the first initial clinical experiences, a novel treatment modality was designed for untreated, 
newly diagnosed myeloma patients. This trial involved an autologous transplant followed 2 to 4 
months later by a low-dose total-body irradiation–based nonmyeloablative allograft.17 The rationale 
for this so-called “tandem autologous-allogeneic” approach was to separate in time the high-dose 
cytoreduction with melphalan at standard 200 mg/m
2
 and the graft-versus-myeloma effect with the 
potential of drastically reducing treatment-related toxicity. The very first multicenter prospective 
experience of the “Seattle Consortium” included 54 stage II-III newly diagnosed patients, median 
age 52 years, half of them with refractory or relapsed disease.
17
 Fifty-two of 54 patients completed 
the protocol. Complete remission was reported in 57%, and overall transplant-related mortality was 
reduced to 22%. After a median follow-up of 60 months, overall and progression-free survivals 
were 69% and 38%, respectively. 
Long-term outcomes of 102 patents treated with this tandem approach after a follow-up of 6.3 years 
were recently described by the same investigators.
34
 However, unlike the previous study, patients 
were not uniformly in first-line treatment. Overall, 42% of patients developed grade II-IV acute 
GvHD and 74% experienced chronic GvHD. Transplant-related mortality at 5 years post-
allografting was 18%, primarily due to GvHD and/or infections. Overall response rate was 94%, 
with 65% and 29% of patients achieving complete and partial remissions, respectively. Median time 
to progression was 5 years. Median overall survival was not reached and progression-free survival 
was 3 years. Estimated 5-year overall and progression-free survivals were 64% and 36%. 
The Gruppo Italiano Trapianti di Midollo recently reported their experience with the same tandem 
approach.
26
 One hundred newly diagnosed patients younger than 65 years were enrolled in a 
prospective multicenter study. A major strength of the study was the strict enrollment of untreated 
myeloma patients who underwent the same vincristine, doxorubicin, and dexamethasone (VAD)-
based induction chemotherapy before the autologous cytoreductive transplant. This strategy meant 
that all patients were treated uniformly and any statistical bias was greatly reduced. Primary 
endpoints were overall and event-free survivals from diagnosis. After a median follow-up of 5 
years, overall survival was not reached and event-free survival was 37 months. Incidences of acute 
and chronic GvHD were 38% and 50%, respectively. Complete remission was achieved in 53% of 
patients. Complete or very good partial remission prior to allografting was significantly associated 
with achievement of post-transplant remission and longer event-free survival. Interestingly, both the 
Seattle study and that from the Italian group concluded that graft-versus-myeloma effects were not 
associated with clinical GvHD. 
In recent years, a number of other reduced-intensity regimens have been developed and employed 
in clinical trials, including melphalan 100-140 mg/m
2
 with or without fludarabine, 200 cGy total 
body irradiation with/without fludarabine, and intermediate-dose busulfan. Furthermore, anti-
thymocyte globulin or the anti-CD52 antibody alemtuzumab have been employed in some trials to 
reduce GvHD.
35, 36, 37, 38, 39, 40, 41 and 42
 Overall, despite the high number of conditionings, a planned 
autograft followed by a nonmyeloablative or reduced-intensity allograft with G-CSF–mobilized 
PBHCs appears to be the most widely used transplant approach.
17
 
The EBMT group reported a comparison between 321 transplants after reduced-intensity 
conditionings and 196 transplants after myeloablative conditionings performed in 103 EBMT Units 
between 1998 and 2002.
43
 The two cohorts of patients were significantly different. Patients in the 
reduced-intensity group were older, median age 51 versus 45 years, more commonly with 
progressive disease, 28% versus 21%, and more heavily pretreated including one or more 
autologous transplants, 76% versus 11%. Although transplant-related mortality was significantly 
lower in the reduced-intensity group, 24% versus 37% at 2 years, no statistical differences in overall 
and progression-free survivals were observed between the two cohorts primarily due to significantly 
higher relapse in the reduced-intensity cohort. The conclusions of this retrospective study should be 
considered with a degree of caution as many statistical biases are evident between the two cohorts. 
More recently, studies comparing allografting after reduced-intensity conditionings and autografting 
have been published. An Italian study reported on 245 consecutive untreated myeloma patients, up 
to the age of 65 years, diagnosed between 1998-2004 where 162 of 199 with at least one sibling 
were HLA-typed with their potential sibling donors.
44
 This trial was based on the concept of 
Mendelian or genetic randomization, which relies on the biological process through which offspring 
randomly inherit genetic traits half from each parent so that one in four siblings is expected to have 
a potential HLA-identical sibling donor. The new feature was the treatment assignment in function 
of the presence or absence of an HLA-identical sibling donor. The comparison by the intention-to-
treat principle between patients with and without HLA-identical siblings was used as a surrogate for 
an unbiased randomization. All patients received induction with VAD-based regimens followed by 
an autograft with melphalan. Eighty patients with an HLA-identical sibling were offered total body 
irradiation–based nonmyeloablative conditioning followed by an allograft with G-CSF–mobilized 
PBHCs, whereas 82 patients without an HLA-identical sibling were assigned to receive a second 
autograft after high-dose (140-200 mg/m
2
) or intermediate-dose (100 mg/m
2
) melphalan. At a 
median follow-up of 45 months, overall and event-free survivals were significantly longer in 
patients with donors: 80 versus 54 months and 35 versus 29 months, respectively. By multivariate 
analysis, having an HLA-identical sibling was an independent variable significantly associated with 
longer overall and event-free survivals. Overall, 58 and 46 patients completed the tandem 
autologous-allogeneic and the tandem autologous programs, with complete remission rates of 55% 
versus 26%, respectively. Transplant-related mortality was 10% and 2%, respectively. Median 
overall survival was not reached in the tandem autologous-allogeneic cohort and was 58 months in 
the tandem autologous cohort. Event-free survivals were 43 and 33 months, respectively. This study 
was recently updated
45
 after a median follow-up of 6 years. Overall survival was not reached for the 
80 patients with an HLA-identical sibling and was 52 months for those without (P = .004); event 
free survival remained significantly longer in patients with HLA-identical siblings: 35 versus 29 
months (P = .009). Moreover, the median overall survival was not reached in the 58 patients who 
completed the tandem autologous-allogeneic program and was 64 months in the 46 patients who 
completed the high-dose melphalan double autologous program (P = .04). Event-free survivals were 
37 and 33 months (P = .06). 
Another French study compared two trials that enrolled high-risk myeloma patients in the light of 
elevated serum β2-microglobulin and del(13).
46
 All patients underwent an autograft after melphalan 
at 200 mg/m
2
. Sixty-five patients with HLA-identical sibling donors were then treated with an 
allograft after a conditioning consisting of busulfan, fludarabine, and high-dose anti-thymocyte 
globulin, 12.5 mg/kg. These patients were compared with 219 high-risk patients who were treated 
with a second autograft after melphalan at 220 mg/m
2
. Transplant-related mortality and response 
rates were not significantly different. At a median follow-up of 2 years, overall and event-free 
survivals were 35% and 25%, and 41% and 30% for the double autologous and the autologous-
allogeneic cohorts. These findings may indicate that patients with disease features such as del(13) 
and high β2-microglobulin may not benefit from a reduced-intensity allograft. Although the 
incidence of chronic GvHD was 7%, the high dose of anti-thymocyte globulin may have prevented 
potentially curative graft-versus-myeloma effects. This study was also recently updated. 
47
 As of 
July 1, 2008, by intent-to-treat analysis on all 284 patients, at a median follow-up of 56 months, 
event-free survival did not significantly differ between tandem autologous and a single autograft 
followed by a reduced-intensity allograft (median, 22 v 19 months; P = .58). There was a trend for a 
superior overall survival in the tandem autologous trial (median, 48 v 34 months; P = .07). Similar 
results were observed when the two cohorts of patients who completed the programs were 
compared. Indeed, newer biological parameters such as genetic abnormalities have been widely 
used for categorizing patients. Chromosome 13 deletion, detected by standard cytogenetics or 
fluorescence in situ hybridization (FISH), has been the genetic abnormality most frequently 
associated with worse prognosis in a number of studies. 
48, 49, 50 and 51
 However, a recent more 
comprehensive analysis clearly showed that chromosome 13 deletion alone did not affect overall 
survival after transplant unless it was associated with other abnormalities such as translocation 4;14 
and chromosome 17 deletion. 
52
 In the light of these findings, the impact of genetic abnormalities 
after an allograft should be evaluated with more comprehensive analyses that include all the 
chromosomal abnormalities associated with multiple myeloma rather than single abnormalities. 
A third genetically randomized study was recently reported by the Spanish group.
53
 One hundred 
ten patients who failed to reach at least near-complete remission after a first autograft were 
scheduled to receive either a second autograft (n = 85) or an allograft (n = 25) after a reduced-
intensity conditioning with melphalan and fludarabine. There was a higher complete remission rate 
(40% v 11%, P = .001), and a trend towards a longer progression-free survival (median, 31 months 
v not reached; P = .08) in the reduced-intensity group. However, patients who underwent an 
allograft showed a trend towards a higher transplant-related mortality (16% v 5%, P = .07) and no 
statistical difference in overall and event-free survivals. 
Finally, two large prospective randomized studies, the BMT-CTN-0102 trial in the United States 
and the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) trial in Europe, have 
recently been presented. However, their final analyses are not yet available. 
 
GvHD and T-Cell Depletion 
 
Overall, GvHD and its complications account for most transplant-related mortality. However, the 
incidence of GvHD may be reduced in the future when its pathogenesis becomes clearer. For 
example, a conditioning of marrow-sparing total lymphoid irradiation and anti-thymocyte globulin 
was shown to decrease GvHD incidence to 3% without affecting graft-versus-leukemia effects.
54
 
T-cell depletion has been rather extensively used to eliminate GvHD even though this approach has 
invariably been associated with a higher risk of relapse of the underlying malignancies.
55
 Although 
limited in myeloma patients, partial T-cell depletion to allow donor engraftment and reduce the risk 
of GvHD has been employed by Alyea et al. Patients were infused with CD6-depleted donor bone 
marrow grafts after a myeloablative conditioning. Selected CD4
+
-donor lymphocytes were 
scheduled later to enhance graft-versus-myeloma effects.
56
 The incidence of grade II-III GvHD was 
21%, and transplant-related mortality was dramatically reduced to 10%. Only one patient achieved 
a complete remission at 6 months without the addition of donor lymphocytes. Fourteen of 24 
patients received donor lymphocyte infusions and disease response was observed in 10 patients. 
However, seven of 10 developed acute or chronic GvHD. Two-year overall and progression-free 
survivals were 55% and 42%, respectively. 
The use of the monoclonal anti-CD52 antibody alemtuzumab has also been rather extensively 
explored to reduce the incidence of GvHD, either by the so-called treatment “in the bag” or by 
systemic intravenous infusion before the conditioning.
57
 Alemtuzumab reduced GvHD, but at the 
same time its use remarkably affected response rates and response duration. These findings further 
confirm the pivotal role of donor T cells in providing graft-versus-myeloma activity. Lokhorst et al 
on behalf of the HOVON group reported on 53 patients with an HLA-identical sibling who 
underwent a partially T-cell–depleted allograft as first-line treatment.58 The overall response rate 
was 89% with 19% complete remissions. At a median follow-up of 38 months, 20 patients were 
alive and 33 dead, 14 from progressive disease and 18 from transplant-related mortality. Overall 
and progression-free survivals after allografting were 17 and 25 months. Unfortunately, only three 
patients were in continuous clinical remission. These findings did not support the use of T-cell–
depleted myeloablative allografting in myeloma. 
Overall, although GvHD was associated with disease response in most clinical trials employing 
myeloablative conditionings, it is encouraging that, by contrast, recent studies employing T-repleted 
transplants after nonmyeloablative conditionings have not correlated disease response and its 
duration with the development of acute or chronic GvHD.
26 and 34
 
 
Allografting: Future Perspectives 
 
Whether an allograft should be part of a first-line treatment plan or of salvage therapy for 
refractory/relapsed patients is still hotly debated.
59
 Although allografting with reduced-
intensity/nonmyeloablative conditioning has evolved into a less toxic procedure, new methods to 
augment graft-versus-myeloma effects to allow long-term disease control and possibly decrease 
toxicity are currently sought. For this purpose, new drugs such as thalidomide, lenalidomide, and 
bortezomib should not be viewed as mutually exclusive with an allograft. They may be employed to 
achieve profound cytoreduction before allograft and enhance graft-versus-myeloma effects as 
maintenance therapy afterwards.
60, 61, 62 and 63
 
In summary, current clinical observations suggest that allografting may be an effective treatment at 
least in a subset of multiple myeloma patients. The possible combination of graft-versus-myeloma 
effects with “new drugs” should be clinically explored in well-designed phase III clinical trials. 
Control groups should include patients treated with new agents with potent anti-myeloma activity 
with/without autografting. Moreover, stratification of patients by prognostic factors, especially 
chromosomal abnormalities, is indispensable to determine the patient subgroup that may most 
benefit from an allograft and to explain discrepancies seen in recently published studies. Moreover, 
in the future, other advanced technologies such as gene-expression profiling may be able to predict 
the biological behavior of the disease and determine how these factors influence graft-versus-
myeloma effects.
64, 65 and 66
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